Time filter

Source Type

Jiayi Shi, Taiwan

Wu Y.-F.,Buddhist Tzu Chi General Hospital | Wang T.-F.,Buddhist Tzu Chi General Hospital | Chu S.-C.,Buddhist Tzu Chi General Hospital | Huang K.-P.,Buddhist Tzu Chi General Hospital | And 5 more authors.
Journal of Internal Medicine of Taiwan | Year: 2011

Objectives: The combination of cisplatin and vinorelbine has been proved to be effective and safe in the therapy of advanced breast cancer. We reported the experience of treating advanced breast cancer with combination of cisplatin and vinorelbine (PVn) as second line palliative regimen in Hualien Buddhist Tzu Chi General Hospital. Study design: Retrospectively, we analyzed thirty patients who underwent the regimen of PVn between Oct. 2002 and Sep. 2008. Patients received cisplatin (75mg/m2) on day 1 and vinorelbine (25mg/m2) on day 1 and 8 by intravenous infusion in every three weeks. Treatment was repeated for up to six cycles. The effectiveness and complications of the regimen were analyzed. Results: Among 30 patients, there were 21 patients with objective responses (70%), including 4 complete responses (13.3%) and 17 partial responses (56.7%). Time to progression was 7.79 months, and overall survival was 13.2 months. Grade 3 or 4 neutropenia was observed in 15 patients (63.3%), and neutropenic fever developed in 11 patients (36.7%). There was no treatment-related mortality. Conclusion: The combination of cisplatin and vinorelbine is effective and with modest toxicity as a palliative regimen in advanced breast cancer. Source

Wang A.-Y.,Yuanpei University | Kuo C.-L.,Mackay Memorial Hospital | Lin J.-L.,Yuanpei University | Fu C.-M.,National Taiwan University | Wang Y.-F.,Dalin Tzu Chi General Hospital
Journal of Radioanalytical and Nuclear Chemistry | Year: 2010

This study examined the applications of novel non-polymer magnetic ferrite nanoparticles (Fe3O4 NPs) labeled with 99mTc-pertechnetate (99mTcO4 -). The radiochemistry, chemistry, and biodistribution of Fe3O4 NPs labeled with 9mTcO4 - were analyzed. This paper employed instant thin layer chromatography and magnetic adsorption to evaluate the labeling efficiency and stability of 99mTc-Fe 3O4 at various reaction conditions. A scanning electron microscope, X-ray diffractometer, Fourier transform infrared spectrometer, laser particle size analyzer, and superconducting quantum interference device magnetometer were used to analyze the physical and chemical properties of the Fe3O4 and 99Tc-Fe3O4 nanoparticles. The biodistribution and excretion of 99mTc-Fe 3O4 were also investigated. Radiochemical analyses showed that the labeling efficiency was over 92% after 1 min in the presence of a reducing agent. Hydroxyl and amine groups covered the surface of the Fe 3O4 particles. Therefore, 99Tc (VII) reduced to lower oxidation states and might bind to Fe3O4 NPs. The sizes of the 99Tc-Fe3O4 NPs were about 600 nm without ultrasound vibrations, and the particle sizes were reduced to 250 nm under ultrasound vibration conditions. Nonetheless, Fe3O4 NPs and 99Tc-Fe3O4 NPs exhibited superparamagnetic properties, and the saturation magnetization values were about 55 and 47 emu/g, respectively. The biodistribution showed that a portion of the 99mTc-Fe3O4 nanoparticles might embolize in a pulmonary capillary initially; the embolism radioactivity was cleared from the lungs and was then taken up by the liver. 99mTc-Fe3O 4 metabolized very slowly only 1-2% of the injected dose (ID) was excreted in urine and about 2.37% ID/g was retained in the liver 4 h after injection. Radiopharmaceutically, 99mTc-Fe3O4 NPs displayed long-term retention, and only 99mTc-Fe 3O4 NPs that dissociated to free pertechnetate could be excreted in urine. This research evaluated the feasibility of non-polymer magnetic ferrite NPs labeled with technetium as potential radiopharmaceuticals in nuclear medicine. © 2010 Akadémiai Kiadó. Source

Huang T.-T.,University of Texas Health Science Center at San Antonio | Huang T.-T.,Changhua Christian Hospital | Huang T.-T.,National Chung Cheng University | Gonzales C.B.,University of Texas Health Science Center at San Antonio | And 12 more authors.
Carcinogenesis | Year: 2013

DNA hypermethylation of promoter CpG islands is associated with epigenetic silencing of tumor suppressor genes in oral squamous cell carcinomas (OSCCs). We used a methyl-CpG-binding domain protein capture method coupled with next-generation sequencing (MBDCap-seq) to survey global DNA methylation patterns in OSCCs with and without nodal metastasis and normal mucosa (total n = 58). Of 1462 differentially methylated CpG islands identified in OSCCs relative to normal controls, MBDCap-seq profiling uncovered 359 loci linked to lymph node metastasis. Interactive network analysis revealed a subset of these loci (n = 23), including the anaplastic lymphoma kinase (ALK) gene, are potential regulators and effectors of invasiveness and metastatic progression. Promoter methylation of ALK was preferentially observed in OSCCs without node metastasis, whereas relatively lower methylation levels were present in metastatic tumors, implicating an active state of ALK transcription in the latter group. The OSCC cell line, SCC4, displayed reduced ALK expression that corresponded to extensive promoter CpG island methylation. SCC4 treatment with demethylating agents induced ALK expression and increased invasion and migration characteristics. Inhibition of ALK activity in OSCC cells with high ALK expression (CAL27, HSC3 and SCC25), decreased cell growth and resulted in changes in invasive potential and mesenchymal marker expression that were cell-line dependent. Although ALK is susceptible to epigenetic silencing during oral tumorigenesis, overwriting this default state may be necessary for modulating invasive processes involved in nodal metastases. Given the complex response of OSCC cells to ALK inhibition, future studies are required to assess the feasibility of targeting ALK to treat invasive OSCCs. © The Author 2013. Published by Oxford University Press. All rights reserved. Source

Evens A.M.,Northwestern University | Jovanovic B.D.,Northwestern University | Su Y.-C.,Dalin Tzu Chi General Hospital | Raisch D.W.,University of New Mexico | And 11 more authors.
Annals of Oncology | Year: 2011

Background: Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined. Methods: We completed a comprehensive literature search of all published rituximab-associated HBV-R cases and from the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) MedWatch database. Literature and FDA cases were compared for completeness, and a meta-analysis was completed. Results: One hundred and eighty-three unique cases of rituximab-associated HBV-R were identified from the literature (n = 27 case reports, n = 156 case series). The time from last rituximab to reactivation was 3 months (range 0-12), although 29% occurred >6 months after last rituximab. Within FDA data (n = 118 cases), there was a strong signal for rituximabassociated HBV-R [proportional reporting ratio = 28.5, 95% confidence interval (CI) 23.9-34.1; Empiric Bayes Geometric Mean = 26.4, 95% CI 21.4-31.1]. However, the completeness of data in FDA reports was significantly inferior compared with literature cases (P < 0.0001). Among HBV core antibody (HBcAb(+)) series, the pooled effect of rituximab-based therapy showed a significantly increased risk of HBV-R compared with nonrituximab-treated patients (odds ratio 5.73, 95% CI 2.01-16.33; Z = 3.33, P = 0.0009) without heterogeneity (χ2 = 2.12, P = 0.5473). Conclusions: The FDA AERS provided strong HBV-R safety signals; however, literature-based cases provided a significantly more complete description. Furthermore, meta-analysis of HBcAb(+) series identified a more than fivefold increased rate of rituximab-associated HBV-R. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Source

Wang Y.-F.,Dalin Tzu Chi General Hospital | Wang Y.-F.,Tzu Chi University | Huang H.-Y.,National Chung Hsing University | Huang H.-Y.,Wufeng University | And 5 more authors.
Journal of Food and Drug Analysis | Year: 2012

Current pharmacological therapy for gastroparesis is limited by a few optional agents with high side effect profiles. Probiotics, which exert both prokinetic and antibiotic properties, can be a good alternative. This study investigates the effects of capsules containing three species of Lactobacillus on gastric emptying function by using a crossover placebo-controlled clinical trial. The 15 healthy participants recruited were divided into two groups, with one group of 7 persons aged between 20-40 and another group of 8 persons aged between 41-60. All the participants in each group were provided with placebo capsules and probiotic capsules, respectively, to be taken twice a day after meals for 3 weeks with crossover in the following 3 weeks. Tc-99m scintigraphy was performed at the beginning of weeks 0, 3 and 6 to determine the gastric emptying rate. All time-activity curves were constructed and the half time of gastric emptying (GEt1/2) was calculated for the same subject for comparison. The GEt1/2 of the baseline, placebo and Lactobacillus regimen periods for the 20-40 age group were 73.0 ± 16.0, 85.7 ± 10.5, and 87.8 ± 10.0 min, respectively, while those for the 41-60 age group were 79.1 ± 23.9, 70.9 ± 33.1, and 68.4 ± 15.2 min, respectively. Comparison of the two groups showed a positive effect of probiotics capsules on the 41 to 60-year-old participants (p = 0.013) but not on the 20 to 40-year-old participants. There was no significant statistical difference between the two groups in the period of treatment with placebo. This early stage trial indicated that the multi-strain Lactobacillus capsule is safe and the results provided some evidence that it accelerated gastric emptying in healthy adults above 40 years of age and may become a therapeutic approach in future trials for pathological gastric emptying delay, by implication, especially in diabetic gastroparesis. Source

Discover hidden collaborations